WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.

New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the European Union (EU) to treat adults with ...

AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.

NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.

Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).

Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.

Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...

Agomelatine is a small molecule commercialized by Alto Neuroscience, with a leading Phase II program in Major Depressive Disorder.

PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.